A phase 1, Multi-center, open-label study of IMGN632 administered intravenously in patients with relapsed/refractory CD123-positive acute myeloid leukemia and other CD123-positive hematologic mali

Administered By

Contributors

Start/End

  • October 31, 2018 - October 31, 2023